SME Times is powered by   
Search News
Just in:   • Indian equity indices end slightly lower ahead of RBI's MPC outcome  • J&K’s Kishtwar selected as aspirational agricultural district under PMDDKY  • Indian stock market opens higher as RBI MPC begins  • Mumbai-Ahmedabad bullet train to be fully operational by 2029: Ashwini Vaishnaw  • Nifty, Sensex see sharp decline this week amid H-1B, pharma tariff concerns 
Last updated: 26 May, 2017  

Cipla.9.Thmb.jpg Cipla's Q4 consolidated net loss at Rs 62 cr

cipla.jpg
   Top Stories
» Indian equity indices end slightly lower ahead of RBI's MPC outcome
» Indian stock market opens higher as RBI MPC begins
» Mumbai-Ahmedabad bullet train to be fully operational by 2029: Ashwini Vaishnaw
» Nifty, Sensex see sharp decline this week amid H-1B, pharma tariff concerns
» Govt stands shoulder to shoulder with entrepreneurs, PM Modi pitches ‘Make in India’ at UP trade show
SME Times News Bureau
Global pharmaceutical firm Cipla on Thursday reported a consolidated net loss of Rs 62 crore for the fourth quarter (Q4) of 2016-17.

According to the company, its consolidated net loss during the quarter under review declined to Rs 62 crore from Rs 93 crore in the corresponding period of 2015-16.

However, Cipla's total income for the fourth quarter increased by 8.1 percent to Rs 3,582 crore from Rs 3,315 crore earned during Q4 of FY16.

"While the quarterly results are off the mark due to a tough operating environment and certain one-offs, we delivered on our goal of improving base EBITDA percentage year-on-year by more than 200 bps," said Umang Vohra, MD and Global CEO, Cipla.

On a full financial year 2016-17 basis, the company reported that its consolidated net profit decreased by 26 percent to Rs 1,006 crore from Rs 1,360 crore in 2015-16.

On the other hand, Cipla's consolidated total income from operations during the fiscal under review edged higher by 6.1 percent to Rs 14,630 crore from Rs 13,790 crore.

"We have achieved significant progress on our identified key priorities and have strengthened our core business through consolidation, complexity reduction and deepening our presence in priority markets," Vohra said.

"This year, we have had good traction on our pipeline with 32 US ANDA filings
and a proof of concept of our capabilities for the respiratory franchise for the advanced markets with approval of Sereflo in UK and Albuterol MDI filing in the US."

The company's Board of Directors has recommended a dividend of Rs. 2 per equity share (face value Rs. 2 per equity share) for the year 2016-17, subject to the shareholders' approval.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹84.00
₹82.25
UK Pound
₹104.65
₹108.10
Euro
₹92.50
₹89.35
Japanese Yen ₹56.10 ₹54.40
As on 25 Jul, 2025
  Daily Poll
Who do you think will benefit more from the India - UK FTA in the long run?
 Indian businesses & consumers.
 UK businesses & consumers.
 Both will gain equally.
 The impact will be negligible for both.
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter